Nogo-A expression in oligodendroglial tumors

Neuropathology

Volumn 31, Issue 1, 2011, Pages 11-19

  Jung, Tae Young ^a   Jung, Shin ^a   Lee, Kyung Hwa ^a   Cao, Van Thang ^a   Jin, Shu Guang ^a   Moon, Kyung Sub ^a   Kim, In Young ^a   Kang, Sam Suk ^a   Kim, Hyung Seok ^a   Lee, Min Cheol ^a  

^a Chonnam National University Research Institute of Medical Sciences   (South Korea)

Author keywords

Astrocytic tumor; Marker; Nogo A; Olig 2; Oligodendroglial tumor

Indexed keywords

GLIAL FIBRILLARY ACIDIC PROTEIN; MICROTUBULE ASSOCIATED PROTEIN 2; OLIGODENDROCYTE TRANSCRIPTION FACTOR 2; PROTEIN NOGO A; TUMOR MARKER;

ARTICLE; ASTROCYTOMA; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OLIGODENDROGLIOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; TUMOR CELL; WESTERN BLOTTING;

ASTROCYTOMA; BLOTTING, WESTERN; BRAIN NEOPLASMS; GLIOMA; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MICROSCOPY, FLUORESCENCE; MYELIN PROTEINS; OLIGODENDROGLIOMA; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 78751486670     PISSN: 09196544     EISSN: 14401789     Source Type: Journal    
DOI: 10.1111/j.1440-1789.2010.01118.x     Document Type: Article

References (23)

1. Louis DN, Holland EC, Cairncross JG. Glioma classification: a molecular reappraisal. Am J Pathol 2001; 159: 779-786.
2. Kleihues P, Louis DN, Scheithauer BW et al. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 2002; 61: 215-229.
3. Motoi M, Yoshino T, Hayashi K et al. Immunohistochemical studies on hauman brain tumors using anti-Leu 7 monoclonal antibody in paraffin-embedded specimens. Acta Neuropathol 1985; 66: 75-77.
4. Mueller W, Eum JH, Lass U et al. No evidence of hSNF5/INI1 point mutations in choroids plexus papilloma. Neuropathol Appl Neurobiol 2004; 30: 304-307.
5. Hoang-Xuan K, Aguirre-Cruz L, Mokhtari K et al. OLIG-1 and 2 gene expression and oligodendroglial tumours. Neuropathol Appl Neurobiol 2002; 28: 89-94.
6. Marie Y, Sanson M, Mokhtari K et al. OLIG2 as a specific marker of oligodendroglial tumour cells. Lancet 2001; 358: 298-300.
7. Ligon KL, Alberta JA, Kho AT et al. The oligodendroglial lineage marker OLIG2 is universally expressed in diffuse gliomas. J Neuropathol Exp Neurol 2004; 63: 499-509.
8. Lu QR, Park JK, Noll E et al. Oligodendrocyte linease genes (OLIG) as molecular markers for human glial brain tumors. Proc Natl Acad Sci USA 2001; 98: 10851-10856.
9. Buss A, Sellhaus B, Wolmsley J etal.Expression pattern of Nogo-A protein in the human nervous system. Acta Neuropathol 2005; 110: 113-119.
10. Wang X, Chun S-J, Treloar H et al. Localization of Nogo-A and Nogo-66 receptor proteins at sites of axon-myelin and synaptic contact. J Neurosci 2002; 22: 5505-5515.
11. Liao H, Duka T, Teng FY et al. Nogo-66 and myelin-associated glycoprotein (MAG) inhibit the adhesion and migration of Nogo-66 receptor expressing human glioma cells. J Neurochem 2004; 90: 1156-1162.
12. Kuhlmann T, Gutenberg A, Schulten HJ et al. Nogo-a expression in glial CNS tumors: a tool to differentiate between oligodendrogliomas and other gliomas? Am J Surg Pathol 2008; 32: 1444-1453.
13. Louis DN, Ohgaki H, Wiestler OD et al. WHO Classification of Tumours of the Central Nervous System, pp. 13-66. Lyon: IARC, 2007.
14. Shi SR, Cote RJ, Yang C et al. Development of an optimal protocol for antigen retrieval: a "test battery" approach exemplified with reference to the staining of retinoblastoma protein (pRB) in formalin-fixed paraffin sections. J Pathol 1996; 179: 347-352.
15. Mason DY, Micklem K, Jones M. Double immunofluorescence labelling of routinely processed paraffin sections. J Pathol 2000; 191: 452-461.
16. Kennedy PG, Watkins BA, Thomas DG et al. Antigenic expression by cells derived from human gliomas does not correlate with morphological classification. Neuropathol Appl Neurobiol 1987; 13: 327-347.
17. Nakagawa Y, Perentes E, Rubinstein LJ. Immunohistochemical characterization of oligodendrogliomas: an analysis of multiple markers. Acta Neuropathol 1986; 72: 15-22.
18. Sung CC, Collins R, Li J et al. Glycolipids and myelin proteins in human oligodendrogliomas. Glycoconj J 1996; 13: 433-443.
19. Reifenberger G, Kros JM, Burger PC et al. Oligodendroglial tumours. Pathology and genetics. In: Kleihues P, Cavenee WK, eds. Tumours of the Nervous System. Lyon: IARC Press, 2000; 55-70.
20. Coons SW, Johnson PC, Scheithauer BW et al. Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer 1997; 79: 1381-1393.
21. Fortin D, Cairncross GJ, Hammond RR. Oligodendroglioma: an appraisal of recent data pertaining to diagnosis and treatment. Neurosurgery 1999; 45: 1279-1291.
22. Kuhlmann T, Remington L, Maruschak B et al. Nogo-A is a reliable oligodendroglial marker in adult human and mouse CNS and in demyelinated lesions. J Neuropathol Exp Neurol 2007; 66: 238-246.
23. Barbashina V, Salazar P, Holland EC et al. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene. Clin Cancer Res 2005; 11: 1119-1128.